Form 4 for AIM AIM ImmunoTech Inc.
Accepted 2026-03-16 00:00:00 ET · period of report 2026-03-16 · accession 0001493152-26-010332 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-16 | 2026-03-12 | AIM | CHEMEROW DAVID I. | Dir | C - Cnv Deriv | $0.00 | +25.0K | 28.4K | +727% | $0 |
| D | 2026-03-16 | 2026-03-12 | AIM | CHEMEROW DAVID I. | Dir | C - Cnv Deriv | $0.00 | -25 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-12 | C | A | 25,000 | $0.00 | 28,441 | D | — | — | |
| 2 | Derivative | Series G Convertible Prefered Stock | 2026-03-12 | C | D | 25 | $0.00 | 0 | D | — · 2026-03-06 to — | 25,000 Common Stock | (F1) The preferred shares are convertible into common stock at a rate of 1,000 shares of common stock per whole preferred share, effectively $1.00 per share of common stock. (F2) None |